Back

Differences in VWF activity in von willebrand disease type 2A patients versus LVAD patients with the acquired von willebrand syndrome.

28 August 2018 (10:05 - 10:55)
Organised by:
Congress Presentation Part of: Predictors of outcome after LVAD implantation Ventricular Assist Devices ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Marc Vanderheyden

Cardiovascular Research Center Aalst, Aalst (Belgium)

6 More presentations in this session

Presentation thumbnail
Expression levels of cTnTs and TnI were modified in the heart of pediatric and adults heart failure (HF) patients after ventricular assist device (VAD) implant
Doctor C. Caselli (Pisa, IT)
Abstract
Presentation thumbnail
Disparities in decisional regret among left ventricular assist device patient and caregiver recipients
Doctor E. Stahl (Atlanta, US)
Abstract Slides
Presentation thumbnail
Changes in plasma neprilysin levels after left ventricular assist device implantation and association with short-term outcomes
Doctor E. Yuce (Izmir, TR)
Abstract Slides
Presentation thumbnail
Pre-operative liver dysfunction is associated with higher mortality rates at 1-year after left ventricular assist device implantation.
Mr R. Muslem (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Invasive exercise haemodynamics predict functional capacity in patients with advanced heart failure implanted with a left ventricular assist device
Doctor A. Koshy (Leeds, GB)
Abstract Slides

Access the full session

Session thumbnail
Predictors of outcome after LVAD implantation

The Event

Event poster

ESC Congress 2018

28 August 2018 10:05 CET
You may be interested in
thumbnail
Congress Session
Devices in acute heart failure
thumbnail
Congress Session
Navigating through heart failure device therapies
thumbnail
Congress Session
Which device might help your HFpEF patient?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources